Related Experiment Video
Updated: May 15, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Ospemifene, vulvovaginal atrophy, and breast cancer
Gregory T Wurz1, Lin H Soe2, Michael W DeGregorio1
1University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA 95817, USA.
Abstract:
The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted.
Related Concept Videos
Disorders of the Female Reproductive System
Menopause
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Oogenesis
Drugs that Destabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
